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Thmoxifen, a nonsteroidal antiestrogen, is the endocrine treatment of choice for all
stages of breast cancer in pre- and postmenopausal women. Estrogens stimulate
the proliferation of target cells by transcriptional mechanisms after binding to the
estrogen receptor. The drug tamoxifen competes with estrogen for binding to the
receptor. In this thesis the effects of tamoxifen on the female genital tract and
psychosexual functioning are studied.
After a general introduction, in chapter L a review is given of the effects of
tamoxifen on the female genital tract includhg psychosexual effects.'Ihe English-
language literature in MEDLINE and reference lists from selected articles were
used, with special interest in differentiation of side effects in premenopausal and
postmenopausal women. The most frequently reported side effect was hot
flashes, and the most discussed side effect was the increased endometrial cancer
risk. Weighted estimates of severeness and extent of side effects r,vere mostly not
possible because of lack of randomized trials. Only the risk of endometrial cancer
in relation to tamoxifen treatment could be estimated, being two- to three-fold.
The gynecologic side effects of tamoxifen are diverse and reflect the complexity of
its mechanism of action, with agonistic and antagonistic effects on various tissues,
depending on the ambient serum estradiol concentration and hence menopausal
status of the patient. The issue of endometrial surveillance and possible options
for screening and intervention to abate side effects are discussed.
In chapter 2 the clir-rical implications of the effects of tamoxifen on the
postmenopausal endometrium are discussed. In chapter 2.'L we describe the
tamoxifen effects on the endometrium in postmenopausal breast cancer patients
by transvaginal ultrasonography (TVU), hysteroscopy and histology of
endometrial samples. Out of 53 asymptomatic postmenopausal breast cancer
patients 58% had an increased endometrial thickness and abnormal appearance of
the endometrium on TVU, suggesting endometrial pathology. Hysteroscopy
revealed endometrial polyps in 22"k of them, histologically characterized as
glandulocystic atrophy, with dilated glands and dense stroma. However, in the
majority of the patients no hysteroscopic or histologic explanation for the
thickened endometrium on TVU could be found. In three hysterectomy
specimens, histology of the total endometrial layer showed a similar
glandulocystic atrophy as was found in the polyps and these findings explain the
discrepancy between TVU and hysteroscopy/histology. Due to the high number
of false-positive findings, we conclude that TVU is not an effective screening
instrument for the endometrium in postmenopausal tamoxifen users.
Chapter 2.2 describes a case report of a patient who developed adenosarcoma of
the uterus after two years of adjuvant tamoxifen treatment for breast cancer. The
possible association between tamoxifen treatment and uterine sarcoma is
discussed and the literature is reviev.red.
In chapter 2,3 a contribution to the discussion concerning the useful-ness of
endometrial surveillance in tamoxifen users, in response to the studies of Barakat
et a1.' and Love et al.'?is given. We discuss the explanation for thc discrepancy
between TVU versus hysteroscopy and histology, and the high false-positive rate
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of ultrasonographic filrdings i.e. the characteristic endometrial stromal and
epithelial reactions to tamoxifen as described in chapter 2.1. We recommend that
all tamoxifen treated patients should be instructed and encouraged to report to
their doctor abnormal vaginal bleeding or discharge. Only those patients who
present with symptoms should have a hysteroscopy with endometrial sampling,
to exclude or diagnose endometrial cancer.
In chapter 3 tamoxifen effects on epithelial proliferation and estrogen receptor
and progesterone receptor expression were analvzed in 125 samples of
postmenopausal endometrium. In benign endometrial epithelium, the
proliferation index by Ki-67 expression was higher in tamoxifen users (13%) than
in non-users (2%).In endometrial cancer the proliferation index was higher than
in benign endometrium, but similar in tamoxifen users (32%) and non-users
(35%). Estrogen receptor expression was comparably high in benign epithelium
from tamoxifen users (97%) andnon-users (92%), but lower in endometrial cancer
occurring in tamoxifen users (60% vs. 88%). In stromal cells the progesterone
receptor expression was higher in tamoxifen users, both in benign (84% vs. 54%)
and malignant endometrium (33% vs. 10%). The observed higher proliferation
rate in endometrial epithelium from tamoxifen users might play a role in the
observed higher incidence of endometrial cancer in tamoxifen users. The higher
progesterone receptor expression in tamoxifen exposed stromal cells suggests an
estrogenic effect on the endometrial stroma, independent of the histologic
diagnosis.
In chapter 4 apoptosis and apoptosis-associated parameters in the endometrium
of tamoxifen-exposed and non-exposed women are studied. Endometrial tissue
samples from 125 postmenopausal women with benign or malignant
endometrium with and without tamoxifen-exposure were examined. Apoptosis
was evaluated morphologically by light microscopy and the percentage of
apoptotic cells was expressed as the apoptotic index (AI). In addition, in benign
endometrium from tamoxifen-users and non-users, epithelial cell apoptosis was
evaluated by the expression of caspase-3 and by a neo-epitope on cytokeratin 18,
unmasked by an early caspase-cleavage event and recognizedby the monoclonal
antibody M30. Expression of apoptosis-associated parameters such as Fas, FasL
and Bcl-2 were evaluated in all samples. The AI in benign endometrium was
0.17% in tamoxifen-users and 0.08% in controls, and in endometrial cancer 2.49%
in exposed and 2.26/. in non-exposed endometrium. Le benign endometrium,
apoptosis by the expression of caspase-3 and M30 reactivity was absent in
tamoxifen-users and low or absent in controls and did not correlate with the AI,
Fas, FasL or Bcl-2 expression. Correlation of the AI with the previously reported
Ki-67 index in benign endometrium showed that the AI/Ki-67 index was lower in
tamoxifen-users (0.02) than in non-users (0.05) (p< 0.005). FasL expression was
more frequently expressed in benign epithelium from tamoxifen-users than in
controls (40% vs. 9%, p<0.05), while no changes in the expression of Fas and Bcl-




conclusion, in postmenopausal, benign endometrium, the AI/Ki-67 index in
tamoxifen-users is lower than in controls, indicating an imbalance between cell
death and cell proliferation, in favor of proliferation, together with an increased
FasL expression. These findings imply an imbalance in the apoptosis
/proliferation equilibrium and possibly immunology, in tamoxifen-exposed
endometrium, that might contribute to the increased endometrial cancer risk in
postmenopausal tamoxifen-users.
In chapter 5 patient-related parameters determining ovarian cyst formation in
women using tamoxifen for breast cancer were evaluated. We performed a cross-
sectional study in 742 pre- and postmenopausal breast cancer patients using
tamoxifen. Gynecological assessment, transvaginal ultrasonography (TVU) and
serum estradiol and follicle stimulating hormone analysis were performed. After
the initial examination, follow-up assessments were performed twice a year. Uni-
or bilateral ovarian cysts were detected by TVU in 24 tamoxifen-using patients.
Multiple regression analysis showed that cyst development is related to high
serum levels of estradiol, younger age and absence of high-dose chemotherapy,
indicating a premenopausal status of the patient. No patients older than 50 years
of age, after high-dose chemotherapy or with amenorrhoea over one year and low
levels of estradiol, developed ovarian cysts. Patients still having a menstrual cycle
during tamoxifen had a high chance (over 80%) of developing ovarian cysts.
Thus, breast cancer patients receiving tamoxifen only develop cysts if their
ovaries are able to respond to ovarian stimulation by a high estradiol production.
In chapter 6 the impact of tamoxifen on subjective and psychosexual well-being
in relation to type of prior chemotherapy and menopausal status was studied.
Patients participated in a randomized study comparing adjuvant standard-dose
and high-dose chemotherapy in breast cancer patients under 56 years of age,
followed by two years of daily 40 mg tamoxifen. Every six months during
tamoxifen treatment and once after cessation, a structured interview was
performed, containing items of physical, mood-related and psychological
symptoms associated with tamoxifen and menopause. During tamoxifen the most
frequent complaints were hot f lashes, disturbed sleep, vaginal dryness,
dyspareunia, decreased sexual desire and musculo-skeletal symptoms. Disturbed
sleep correlated with hot flashes and concentration problems while decreased
sexual desire correlated with vaginal dryness and dyspareunia. In the high-dose
arm all except one patient became postmenopausal and more patients reported
symptoms than in the standard-dose arm. After discontinuation of tamoxifen,
symptoms decreased. However, hot flashes, disturbed sleep and vaginal dryness
persisted more often in patients who had become postmenopausal due to (high-
dose) chemotherapy.
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